AFM
CNSP icon

Anson Funds Management’s CNS Pharmaceuticals CNSP Stock Holding History

Anson Funds Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-236
Closed -$223K – 166
2024
Q2 		$223K Buy
+236
New +$1.26M 0.03% 141

Other funds holding CNSP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Anson Funds Management's CNSP Position: Q3 2024 in Review

Anson Funds Management sold out of CNS Pharmaceuticals (CNSP) in Q3 2024, closing a stake of 236 shares — an estimated $223K sold.

Anson Funds Management first reported a position in CNSP in Q2 2024 and held it in 1 quarter. The position peaked at $223K in Q2 2024. 7 funds tracked by Wall St. Rank hold CNSP as of Q3 2024.

  • Anson Funds Management reported no remaining CNS Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Anson Funds Management sold 236 CNS Pharmaceuticals shares in Q3 2024, an estimated $223K.
  • Anson Funds Management first reported a position in CNS Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Anson Funds Management's CNS Pharmaceuticals position peaked at $223K in Q2 2024.
  • 7 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q3 2024.

Based on Anson Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.